Atty. Dkt. No. 038602-1060

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Narmada SHENOY et al.

Title: FORMULATIONS FOR PHARMACEUTICAL AGENTS IONIZABLE AS FREE ACIDS OR FREE BASES

Appl. No.: 09/716,332

Filing Date: 11/21/2000

Examiner: Unassigned

Art Unit: 1615

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
Box PATENT APPLICATION
Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1:56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

Atty. Dkt. No. 038602-1060

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits, and within three (3) months of the mailing date of the foreign search report.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

References A11- A13, A33, A36 and A43-A47 were all cited in the corresponding International Search Report. A copy is attached for your convenience. The remaining references were cited in related patents and/or co-pending related applications.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date August 30, 2001

By Mary C Lee Reg. #41,545
for Beth A. Burrous
Attorney for Applicant
Registration No. 35,087

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5475
Facsimile: (202) 672-5399

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: **038602/1060**	SERIAL NO. : **09/716,332**
		APPLICANT: Narmada SHENOY, et al.	
INFORMATION DISCLOSURE CITATION			
		FILING DATE: 11/21/2000	GROUP ART UNIT: 1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	A1	4,002,749	01-11-77	Rovnyak et al.	424	246	08-12-75
	A2	4,053,613	10-11-77	Rovnyak et al.	424	246	09-17-75
	A3	4,966,849	10-30-90	Vallee et al.	435	199	2-2-89
	A4	5,217,999	06-08-93	Levitzki et al.	514	613	3-24-92
	A5	5,302,606	04-12-94	Spada et al.	514	357	4-16-91
	A6	5,330,992	07-19-94	Eissenstat et al.	514	312	10-23-92
	A7	5,786,488	07-28-98	Tang et al.	548	455	11-5-97
	A8	5,792,783	08-11-98	Tang et al.	514	397	6-5-96
	A9	5,840,745	11-24-98	Buzzetti et al.	514	414	12-22-95
	A10	5,880,141	03-09-99	Tang et al.	514	339	6-7-95
	A11	5,883,113	03-16-99	Tang et al.	514	418	6-5-96
	A12	5,883,116	03-16-99	Tang et al.	514	418	6-5-98
	A13	5,886,020	03-23-99	Tang et al.	514	418	6-5-96
	A14	Re 36,256	07-20-99	Spada et al.	514	249	12-10-97

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES/NO
	A15	91/13055	09-05-91	WO			
	A16	91/15495	10-17-91	WO			
	A17	92/07830	05-14-92	WO			
	A18	92/20642	11-26-92	WO			
	A19	92/21660	12-10-92	WO			
	A20	93/01182	01-2193	WO			
	A21	93/23040	11-25-93	WO			
	A22	94/03427	02-17-94	WO			
	A23	94/10202	05-11-94	WO			
	A24	94/14808	07-07-94	WO			
	A25	95/01349	01-12-95	WO			
	A26	95/14667	06-01-95	WO			
	A27	95/24190	09-14-95	WO			
	A28	96/00226	01-04-96	WO			
	A29	96/16964	06-06-96	WO			
	A30	96/22976	08-01-96	WO			
	A31	96/32380	10-17-96	WO			
	A32	96/40116	12-19-96	WO			

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: **038602/1060**	SERIAL NO. : **09/716,332**
		APPLICANT: Narmada SHENOY, et al.	
INFORMATION DISCLOSURE CITATION			
		FILING DATE: 11/21/2000	GROUP ART UNIT: 1615

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES/NO
	A33	98/07695	02-26-98	WO			
	A34	98/07835	02-26-98	WO			
	A35	98/24432	06-11-98	WO			
	A36	98/38984	09-11-98	WO			
	A37	98/45708	10-15-98	WO			
	A38	98/50356	11-12-98	WO			
	A39	98/56376	12-17-98	WO			
	A40	99/10325	03-04-99	WO			
	A41	99/19325	4-22-99	WO			
	A42	99/48868	09-30-99	WO			
	A43	99/61422	12-02-99	WO			
	A44	00/56709	09-28-00	WO			
	A45	00/38519	07-06-00	WO			
	A46	00/35908	06-22-00	WO			
	A47	00/08202	02-17-00	WO			
	A48	0 252 731 A2	01-13-88	EP			
	A49	0 304 493	03-01-89	EP			
	A50	0 566 226 A1	10-20-93	EP			
	A51	0 934 931 A2	08-11-99	EP			
	A52	0 934 931 A3	08-11-99	EP			
	A53	1 599 772	07-20-70	France			

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	A54		Akbasak and Sunar-Akbasak., "Oncogenes: cause or consequence in the development of glial tumors," J. Neurol. Sci. 111:119-133 (1992)
	A55		Andreani et al., "Synthesis and potential *coanthracyclinic* activity of substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones," Eur. J. Med. Chem. 32:919-924 (1997) ©Elsevier, Paris.
	A56		Andreani et al., "In vivo cardiotonic activity of pyridylmethylene-2-indolinones" Arzneimittel-Forschung Drug Research 48(II): 727-729 (1998)
	A57		Andreani et al., "Synthesis and cardiotonic activity of 2-indolinones," Eur. J. Med. Chem. 25(2):187-190 (1990).
	A58		Arteaga et al., "Blockade of the Type I Somatomedin Receptor Inhibits Growth of Human Breast Cancer Cells in Athymic Mice," J. Clin. Invest. 84:1418-1423 (1989) ©The American Society for Clinical Investigation, Inc.
	A59		Arvidsson et al., "Try-716 in the Platelet-Derived-Growth-Factor β-Receptor Kinase Insert is Involved in GRB2 Binding and Ras Activation," Molecular and Cellular Biology 14(10):6715-6726 (1994) ©The American Society for Microbiology

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: **038602/1060**	SERIAL NO. : **09/716,332**
		APPLICANT: Narmada SHENOY, et al.	
INFORMATION DISCLOSURE CITATION			
		FILING DATE: 11/21/2000	GROUP ART UNIT: 1615

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	A60		Baserga, "Oncogenes and the Strategy of Growth Factors," Cell 79:927-93 (1994) ©Cell Press
	A61		Baserga, "The Insulin-like Growth Factor I Receptor: A Key to Tumor Growth?" Cancer Research 55:249-252 (1995)
	A62		Bolen et al., "The Src family of tyrosine protein kinases in hemopoietic signal transduction," FASEB J. 6:3403-3409 (1992)
	A63		Bolen, "Nonreceptor tyrosine protein kinases," Oncogene 8:2025-2031 (1993) ©MacMillan Press Ltd.
	A64		Bonner et al., "Structure and Biological Activity of Human Homologs of a raf-mil Oncogene," Molecular and Cellular Biology 5:1400-1407 (1985) ©The American Society for Microbiology
	A65		Cance et al., "Novel Protein Kinases Expressed in Human Breast Cancer," Int. J. Cancer 54:571-577 (1993) ©Wiley-Liss, Inc.
	A66		Carpenedo et al., "Identification and Measurement of Oxindole (2-Indolinone) in the Mammalian Brain and Other Rat Organs" Analytical Biochemistry 244:74-79 (1997) ©Academic Press, Inc.
	A67		Chen et al., "Effects of 3,3-Dipyridylmethyl-1-Phenyl-2-Indolinone on γ-Aminobutyric Acid Elicited Chloride Current of Snail Central Neuron" Chinese Journal of Physiology 40(3):149-156 (1997)
	A68		Claesson-Welsh, "Signal Transduction by the PDGF Receptor," Progress in Growth Factor Research 5:37-54 (1994) ©Elsevier Science Ltd.
	A69		Coppola et al., "A Functional Insulin-Like Growth Factor I Receptor is Required for the Mitogenic and Transforming Activities of the Epidermal Growth Factor Receptor," Molecular and Cellular Biology 14:4588-4595 (1994) ©The American Society for Microbiology
	A70		Damiani et al., "Inhibition of Copper-Mediated Low Density Lipoprotein Peroxidation by Quinoline and Indolinone Nitroxide Radicals," Biochemical Pharmacology 48(6):1155-1161 (1994) ©Elsevier Science Ltd.
	A71		Davis et al., "Synthesis and microbiological properties of 3-Amino-1-Hydroxy-2-Indolinone and Related Compounds," Journal of Medicinal Chemistry 16(9):1043-1045 (1973) ©American Chemical Society
	A72		De Vries et al., "The *fms*-Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor," Science 255:989-991
	A73		Decker and Lohmann-Matthes, "A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity," J. Immunol. Methods 15:61-69 (1988) ©Elsevier
	A74		Decodts et al., "Suicide inhibitors of proteases. Lack of activity of halomethyl derivatives of some aromatic lactams," Eur. J. Med. Chem. – Chim. Ther., 18(2):107-111 (1983)
	A75		Dickson et al., "Tyrosine kinase receptor -- nuclear protooncogene interactions in breast cancer," Cancer Treatment Res. 61:249-273 (1992) ©Kluwer Academic Publishers
	A76		Fantl et al., "Distinct Phosphotyrosines on a Growth Factor Receptor Bind to Specific Molecules that Mediate Different Signaling Pathways," Cell 69:413-423 (1992) ©Cell Press
	A77		Fendly et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2-neu Gene product," Cancer Research 50:1550-1558 (1990) (mistakenly referred to as Fendley)
	A78		Ferrara and Henzel, "Pituitary Fillicular Cells Secrete a Novel Heparin-Binding Growth Factor Specific for Vascular Endothelial Cells," Biochemical and Biophysical Research Communications 161:851-858 (1989) ©Academic Press, Inc.

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: 038602/1060	SERIAL NO. : 09/716,332
		APPLICANT: Narmada SHENOY, et al.	
INFORMATION DISCLOSURE CITATION			
		FILING DATE: 11/21/2000	GROUP ART UNIT: 1615

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	A79		Fingl and Woodbury, "Chapter 1 - General Principles," in The Pharmacological Basis of Therapeutics 5th edition, Goodman and Gilman editors, MacMillan Publishing Co., Inc., New York, pp. 1-46 (1975) ©MacMillam Publishing Co., Inc.
	A80		Floege et al., "Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangioproliferative glomerulonephritis," Kidney International 43:369-380 (1993) ©International Society of Nephrology
	A81		Floege et al., "Factors involoved in the regulation of mesangial cell proliferation *in vitro* and *in vivo*," Kidney International 43:S47-S54 (1993) ©International Society of Nephrology
	A82		Folkman and Shing, "Angiogenesis," J. Bio. Chem. 267:10931-10934 (1992) ©The American Society for Biochemistry and Molecular Biology
	A83		Folkman, "Ch. 24. Angiogenesis," Congress of Thrombosis and Haemostasis (Verstraete et al., eds.) Leuven University Press, Leuven pp. 583-596 (1987)
	A84		Folkman, "Tumor Angiogenesis, Therapeutic Implications," New England J. Medicine 285:1182-1186 (1971)
	A85		Folkman, "What Is Evidence that Tumors Are Angiogenesis Dependent?" Journal of National Cancer Institute 82:4-6 (1990)
	A86		Gazit et al., "Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenmalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2-neu tyrosine kinases," J. Med. Chem. 34(6):1896-1907 (1991) ©American Chemical Society
	A87		Gennaro (editor), Remington's Pharmaceutical Sciences (1990) (TABLE OF CONTENTS ONLY)
	A88		Goldring and Goldring, "Cytokines and Cell Growth Control," Critical Reviews in Eukaryotic Gene Expression 1:301-326 (1991)
	A89		Graziani et al., "Hepatocyte Growth Factor/Scatter Factor Stimulates the Ras-Guanine Nucleotide Exchanger," The Journal of Biological Chemistry 268(13):9165-9168 (1993) ©American Society for Biochemistry and Molecular Biology
	A90		Hayler, et al., "Development of Large-Scale Synthesis of Ropinirole in the Pursuit of a Manufacturing Process," Org. Process Res. Dev. 2:(1):3-9 (1998) ©The American Chemical Society and Royal Society of Chemistry
	A91		Hirao et al., "Rhodium-catalyzed carbonylation of 2-alkynylanilines: stynthes of 1,3-dihydroindol-2-ones," Tetrahedron Lett. 36(35):6243-6246 (1995) ©Pergamon
	A92		Honegger et al., "Point Mutation at the ATP Binding Site of EGF Receptor Abolishes Protein-Tyrosine Kinase Activity and Alters Cellular Routing," Cell 51:199-209 (1987) ©Cell Press
	A93		Houck et al. "Dual Regulation of Vascular Endothelial Growth Factor Bioavailability by Genetic and Proteolytic Mechanisms," J. Bio. Chem. 267:26031-26037 (1992) ©American Society for Biochemistry and Molecular Biology, Inc.
	A94		Hu et al., "Interaction of Phosphatidylinositol 3-Kinase-Associated p85 with Epidermal Growth Factor and Platelet-Derived Growth Factor Receptors," Molecular and Cellular Biology 12(3):981-990 (1992) ©Am. Soc. Microbiol.
	A95		Jellinek et al., "Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor," Biochemistry 33:10450-10456 (1994) ©Am. Chemical Society
	A96		Kashishian and Cooper, "Phosphorylation Sites at the C-terminus of the Platelet-Derived Growth Factor Receptor Bind Phospholipase Cγ1, Molecular Biology of the Cell 4:49-57 (1993) ©The American Society for Cell Biology
	A97		Kashishian et al., "Phosphorylation Sites in the PDGF receptor with Different Specificities for Binding GAP and P13 Kinase *in vivo*," The EMBO Journal 11(4):1373-1382 (1992)

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: **038602/1060**	SERIAL NO. : **09/716,332**
		APPLICANT: Narmada SHENOY, et al.	
INFORMATION DISCLOSURE CITATION			
		FILING DATE: 11/21/2000	GROUP ART UNIT: 1615

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	A98		Kato et al., "Simultaneous Determination of Amfenac Sodium and its Metabolite (7-Benzoyl-2-Oxindole) in Human Plasma by High-Performance Liquid Chromatography," Journal of Chromatography 616:67-71 (1993) ©Elsevier Science
	A99		Kazlauskas et al., "The 64-kDa Protein That Associates with the Platelet-Derived Growth Factor Receptor β Subunit via Tyr-1009 Is The SH2-Containing Phosphotyrosine Phosphatase Syp," Proc. Natl. Acad. Sci. USA 90:6939-6942 (1993)
	A100		Kendall and Thomas, "Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor," Proc. Natl. Acad. Sci. USA 90:10705-10709 (1993)
	A101		Kikumoto, et al., "Reactions of oxindoles an disatin with nitrobenzyl chlorides. Formation of 2'-hydroxyspiro'2H-indole-2, 3' –3'H-indole!," Tetrahedron 22(10):3337-3343 (1966) ©Pergamon Press Ltd.
	A102		Kim et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppressed tumor growth in vivo," Nature 362-841-844 (1993)
	A103		Kinsella et al., "Protein Kinase C Regulates Endothelial Cell Tube Formation on Basement Membrane Matrix, Matrigel," Exp. Cell Research 199:56-62 (1992) ©Academic Press Inc.
	A104		Klagsburn and Soker, "VEGF-VPF: The Angiogenesis Factor Found?" Current Biology 3:699-702 (1993) ©Current Biology
	A105		Koch et al., "SH2 and SH3 Domains: Elements That Control Interactions of Cytoplasmic Signaling Proteins," Science 252:668-674 (1991)
	A106		Komada and Kitamura, "The cell dissociation and motility triggered by scatter factor-hepatocyte growth factor are mediated through the cytoplasmic domain of the c-Met receptor," Oncogene 8:2381-2390 (1993)
	A107		Korc et al., "Overexpression of the Epidermal Growth Factor Receptor in Human Pancreatic Cancer is Associated with Concomitant increases in the Levels of Epidermal Growth Factor and Transforming Growth Factor Alpha," J. Clin. Invest. 90:1352-1360 (1992) ©The American Society for Clinical Investigation, Inc.
	A108		Korzeniewski and Callewaert," An Enzyme-Release Assay for Natural Cytotoxicity," J. Immunol. Methods 64:313-320 (1983) ©Elsevier Science Publishers
	A109		Kumabe et al., "Amplification of α-platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin," Oncogene 7:627-633 (1992)
	A110		Lal et al., "Novel diuretic agents. Syntheses of substituted isatylidenes and 3-alkyl or 3-arylalkyl-2-oxindoles, " Indian J. Chem 13(9):898-903 (1975)
	A111		Lee and Donoghue, "Intracellular retention of membrane-anchored v-sis protein abrogates autocrine signal transduction," Journal of Cell Biology 118:1057-1070 (1992) ©The Rockefeller University Press
	A112		Levitzki et al., "Tyrosine kinase inhibition: An approach to drug development," Science 267:1782-1788 (1995)
	A113		Maass et al., "Viral resistance to the thiazolo-iso-indolinoes, a new class of nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase," Antimocrobial Agents and Chemotherapy 37(12)2612-2617 (1993) ©American Society for Microbiology
	A114		Macauley et al., "Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cells," Cancer Research 50:2511-2517 (1990)
	A115		Mariani et al., "Inhibition of angiogenesis by PCE 26806, a potent tyrosine kinase inhibitor," Experimental Therapeutics - Proceedings of the American Association for Cancer Research 35:381 at abstract no. 2268 (March 1994)

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: **038602/1060**	SERIAL NO. : **09/716,332**
		APPLICANT: Narmada SHENOY, et al.	
INFORMATION DISCLOSURE CITATION			
		FILING DATE: 11/21/2000	GROUP ART UNIT: 1615

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	A116		Millauer et al., "High Affinity VEGF Binding and Developmental Expression Suggest Flk-1 as a Major Regulator of Vasculogenesis and Angiogenesis," Cell 72:835-846 (1993) ©Cell press
	A117		Mohammadi et al., "Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors," Science 276(5314):955-960 (1997) ©American Association for the Advancement of Science
	A118		Moreto et al. "3,3-bis-(4-hydroxyphenyl)-7-methyl-2-indolinone (BHMI), the active metabolite of the laxative sulisatin" Arzneimittel-Forschung Drug Research 29(II):1561-1564 (1979)
	A119		Moreto et al., "Study of the laxative properties of the disodium salt of the sulfiuric diester of bis-(4-hydroxyphenyl)-7-methyl-2indolinone(Dan-603) in the rat," European Journal of Pharmacology 36:221-226 (1976) ©North-Holland Publishing Company
	A120		Morrison et al., "Signal Transduction from Membrane to Cytoplasm: Growth Factors and Membrane-Bound Oncogene Products Increases Raf-1 Phosphorylation and Associated Protein Kinase Activity," Proc. Natl. Acad. Sci. USA 85; 8855-8859 (1988)
	A121		Mosmann, "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays," J. Immunol. Methods 65:55-63 (1983) ©Elsevier Publishers B.V.
	A122		Nishimura et al., "Two Signaling Molecules Share a phosphotyrosine-Containing Binding Site in the Platelet-Derived Growth Factor Receptor," Molecular and Cellular Biology 13:6889-6896 (1993)
	A123		Plowman et al., "Receptor Tyrosine Kinases as Targets for Drug Intervention," DN&P 7(6):334-339 (1994)
	A124		Quinn et al., "Fetal Liver Kinase 1 as a Receptor for Vascular Endothelial Growth Factor and is Selectively Expressed in Vascular Endothelium," Proc. Natl. Acad. Sci. USA 90:7533-7537 (1993)
	A125		Rozakis-Adcock et al., "Association of the Shc and Grb2-Sem5 SH2-containing proteins is implicted in activation of the Ras pathway by tyrosine kinases." Nature 360:689-692 (1992)
	A126		Rygaard and Povlsen, "Heterotransplantation of a Human Malignant Tumor to 'Nude' Mice," Acta path. microbiol. scand. 77:758-760 (1969)
	A127		Sainsbury, et al., "Electrochemical oxidation of aromatic ethers. Part 5. Further studies of the coupling reactions of alkoxylated aralkyl and aryl amides," J. Chem. Soc., 1:108-114 (1979)
	A128		Sandberg-Nordqvist et al., "Characterization of Insulin-Like Growth Factor 1 in Human Primary Brain Tumors," Cancer Research 53:2475-2478 (1993)
	A129		Schlessinger and Ullrich, "Growth Factor Signalling by Receptor Tyrosine Kinases," Neuron 9:383-391 (1992) ©Cell Press
	A130		Shibuya et al., "Nucleotide Sequence and Expression of a Novel Human Receptor-Type Tyrosine Kinase Gene (*flt*) closely related to the *fms* family", Oncogene 5:519-524 (1990)
	A131		Singh et al., "Indolinone derivatives as potential antimicrobial agents," Zentralbl. Mikrobiol. 144:105-109 (1989) ©VEB Gastav Fischs veslag.jena
	A132		Singh et al., "Synthesis and Anticonvulsant Activity of New 1-Substituted 1'-Methyl-3-Chloro-2-Oxosprio (Azetidin-3', 4-Indol-2' Ones)," Bollettino Chimico Farmaceutico 133:76-79 (1994)
	A133		Slamon et al., "Studies of the HER-2-neu Proto-oncogene in Human Breast and Ovarian Cancer," Science 244:707-712 (1989)
	A134		Soldi et al., "Platelet-activating factor (PAF) induces the early tyrosine phosphorylation of focal adhesion kinase ($p125^{FAX}$) in human endothelial cells," Oncogene 13(3):515-525 (1996) ©Stockton Press

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: **038602/1060**	SERIAL NO. : **09/716,332**
		APPLICANT: Narmada SHENOY, et al.	
INFORMATION DISCLOSURE CITATION			
		FILING DATE: 11/21/2000	GROUP ART UNIT: 1615

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	A135		Songyang et al., "SH2 Domains Recognize Specific Phosphopeptide Sequences," Cell 72:767-778 (1993) ©Cell Press
	A136		Songyang et al., "Specific Motifs Recognized by the SH2 Domains of Csk, 3BP2, fps-fes, GRB-2, HCP, SHC, Syk and Vav," Molecular and Cellular Biology 14:2777-2785 (1994) ©American Society for Microbiology
	A137		Spada et al., "Small molecule inhibitors of tyrosine kinase activity," Expert Opinion on Therapeutic Patents 5(8):805-817 (1995) ©Ashley Publications
	A138		Sun et al., "Synthesis and biological evaluations of 3-substituted indolin-2-ones: A novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases," J. Med. Chem. 41(14):2588-2603 (1998) ©The American Chemical Society
	A139		Sun et al., "Design, Synthesis, and Evaluations of Substituted 3-[(3-or4-Carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as Inhibitors of VEGF, FGF, and PDGF Receptor Tyrosine Kinases," J. Med. Chem., (42):5120-5130 (1999). ©American Chemical Society
	A140		Superti-Furga et al., "A functional screen in yeast for regulators and antagonizers of heterologous protein tyrosine kinases," Nature Biotech 14:600-605 (1996)
	A141		Superti-Furga et al., "Csk inhibition of c-Src activity requires both the SH2 and SH3 domains of Src," EMBO J. 12:2625-2634 (1993) ©Oxford University Press
	A142		Takano et al., "Inhibition of antiogenesis by a novel diaminoanthraquinone that inhibits protein kinase C," Mol. Bio. Cell 4:358A at abstract no. 2076 (1993)
	A143		Thio et al., "Interconversion of 2-(2-aminophenyl)-3-piperoliidinone and 3-(2-piperidylmethyl)-2-indolinone. Reversible N.dbr.N' transacylation" J. Heterocycl. Chem., 8(3):479-482 (1971)
	A144		Torp et al., "Expression of the Epidermal Growth Factor Receptor Gene in Human Brain Metastases," AMPIS 100:713-719 (1992)
	A145		Traxler, "Protein tyrosine kinase inhibitors in cancer treatment, " Expert Opinion on Therapeutic Patents 7(6):571-588 (1997) ©Ashley Publications Ltd.
	A146		Tsai et al., "The effect of 3,3-Di-Pyridyl-Methyl-1-Phenyl-2-indoline on the nerve Terminal Currents of Mouse Skeletal Muscles," Neuropharmacology 31(9):943-947 (1992) ©Pergamon Press
	A147		Tuzi et al., "Expression of growth factor receptors in human brain tumours," Br. J. Cancer 63:227-233 (1990)
	A148		Twamley-Stein et al., "The Src Family Tyrosine Kinases are Required for Platelet-Derived Growth Factor-Mediated Signal Transduction in NIH 3T3 Cells," Proc. Natl. Acad. Sci., 90:7696-7700 (1993)
	A149		Vaisman et al., "Characterization of the Receptors for Vascular Endothelial Growth Factor," J. Biol. Chem. 265:19461-19466 (1990) ©The American Society for Biochemistry and Molecular Biology
	A150		Varma and Gupta, "Nucleophilic Reactions of 2-Methl-3-(4'-carbomethoxyphenyl)-4-quinazolinones with 2-Indolinones," J. Indian Chem. Soc. 66:804-805 (1989) ©The Indian Chemical Society
	A151		Voller et al., "Ch. 45 - Enzyme-Linked Immunosorbent Assay," in Manual of Clinical Immunology, 2nd edition, Rose and Friedman editors, American Society of Microbiology, Washington, D.C., pp. 359-371 (1980)
	A152		Walker, "The Reduction of Insoindogenides, Nitro Compounds, and Pyridines in a Series of 2-Indolinones," J. Med. Chem. 8(5):626-637 (1965)

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: **038602/1060**	SERIAL NO. : **09/716,332**
		APPLICANT: Narmada SHENOY, et al.	
INFORMATION DISCLOSURE CITATION			
		FILING DATE: 11/21/2000	GROUP ART UNIT: 1615

	A153		Weidner et al. "Tumor Angiogenesis and Metastasis-Correlation in Invasive Breast Carcinoma," New England Journal of Medicine 324(1):1-8 (1991) ©Massachusetts Medical Society
	A154		Wright et al., "Inhibition of Angiogenesis in Vitro and In Ovo With an Inhibitor of Cellular Protein Kinases, MDL 27032," J. Cellular Physiology 152:448-457 (1992)
	A155		Zaman et al., "Tyrosine Kinase Activity of Purified Recombinant Cytoplasmic Domain of Platelet-Derived Growth Factor β-Receptor (β-PDGFR) and Discovery of a Novel Inhibitor of Receptor Tyrosine Kinases," Biochemical Pharmacology 57(1):57-64 (1999) ©Elsevier Science Inc.
	A156		Zhang et al., "Microtubule Effects of Welvistatin, a Cyanobacterial Indolinone that Circumvents Multiple Drug Resistance," Molecular Pharmacology 49:228-294 (1996) ©The American Society for Pharmacology and Experimental Pharmaceutics

EXAMINER	**DATE CONSIDERED**

* **EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with n xt communication to applicant.**